Trials / Active Not Recruiting
Active Not RecruitingNCT02653118
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
A Registry-Based Extension of Protocol V503-001 in Countries With Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, Immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year-Old Women
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,453 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 16 Years – 26 Years
- Healthy volunteers
- Accepted
Summary
Protocol V503-021 is a long-term follow-up study of the V503-001 base study (NCT00543543) to evaluate the safety, immunogenicity, and long-term effectiveness of V503 vaccine in preventing cervical cancer and related precancers caused by human papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58. Because of the high retention of V503-001 participants from the Nordic countries, and the highly efficient screening and surveillance system there, study V503-021 will evaluate only participants from V503-001 sites in Denmark, Norway, and Sweden. The hypothesis is that V503 vaccine will remain effective for at least 30 years after the start of vaccination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V503 | |
| BIOLOGICAL | GARDASIL |
Timeline
- Start date
- 2016-01-22
- Primary completion
- 2040-01-01
- Completion
- 2040-01-01
- First posted
- 2016-01-12
- Last updated
- 2024-11-12
Source: ClinicalTrials.gov record NCT02653118. Inclusion in this directory is not an endorsement.